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Lysosomal perturbations in human 
dopaminergic neurons derived from 
induced pluripotent stem cells with 
PARK2 mutation
Justyna okarmus1,6, Helle Bogetofte  1,6, Sissel Ida Schmidt1, Matias Ryding1, Silvia García-
López2, Brent James Ryan  3, Alberto Martínez-Serrano2, Poul Hyttel4 & Morten Meyer  1,5 ✉
Mutations in the PARK2 gene encoding parkin, an E3 ubiquitin ligase, are associated with autosomal 
recessive early-onset parkinson’s disease (pD). While parkin has been implicated in the regulation of 
mitophagy and proteasomal degradation, the precise mechanism leading to neurodegeneration in both 
sporadic and familial pD upon parkin loss-of-function remains unknown. cultures of isogenic induced 
pluripotent stem cell (ipSc) lines with and without PARK2 knockout (Ko) enable mechanistic studies of 
the effect of parkin deficiency in human dopaminergic neurons. We used such cells to investigate the 
impact of PARK2 KO on the lysosomal compartment and found a clear link between parkin deficiency 
and lysosomal alterations. PARK2 Ko neurons exhibited a perturbed lysosomal morphology with 
enlarged electron-lucent lysosomes and an increased lysosomal content, which was exacerbated by 
mitochondrial stress and could be ameliorated by antioxidant treatment. We also found decreased 
lysosomal enzyme activity and autophagic perturbations, suggesting an impairment of the autophagy-
lysosomal pathway in parkin-deficient cells. Interestingly, activity of the GBA-encoded enzyme, 
β-glucocerebrosidase, was increased, suggesting the existence of a compensatory mechanism. In 
conclusion, our data provide a unique characterization of the morphology, content, and function of 
lysosomes in PARK2 Ko neurons and reveal an important new connection between mitochondrial 
dysfunction and lysosomal dysregulation in pD pathogenesis.
Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting 1–2% of the population. Although 
most PD patients develop late-onset sporadic disease, a subpopulation of patients develops early-onset or familial 
PD forms associated with various genetic mutations. Studying the effects of these mutations can provide valuable 
insights into the molecular pathways and mechanisms that lead to degeneration of dopaminergic neurons in 
PD1–4.
Mutations in the PARK2 gene, encoding the protein parkin, have been identified as the most common 
cause of autosomal recessive early-onset PD and have underlined the importance of mitochondrial dysfunc-
tion in PD pathogenesis5–7. Parkin is a multifunctional E3 ubiquitin ligase involved in several cellular processes. 
Parkin-mediated ubiquitination of mitochondrial proteins8–11 triggers clearance of impaired mitochondria 
through the autophagy-lysosome pathway (ALP)12. Lysosomes are organelles specialized for degrading mac-
romolecules derived from the extracellular space through endocytosis or phagocytosis, or from the cytoplasm 
through autophagy. In recent years, the pathological importance of lysosomes has been indicated by a rap-
idly growing number of human disorders linked to defects in lysosomal function including PD13,14 in which 
non-degraded lipids and misfolded proteins accumulate. Mutations in the GBA gene, coding for the lysosomal 
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glycohydrolase β-glucocerebrosidase (GCase), cause Gaucher’s disease and several studies have reported GBA 
mutations as the numerically greatest genetic risk factor for PD15–17.
A number of studies point to an interplay between mitochondrial homeostasis and proper lysosomal func-
tion. Diseases caused by mutations of ALP proteins often exhibit mitochondrial defects as well18–20. Of relevance 
for PD, loss of GCase activity leads to mitochondrial dysfunction indicating that impaired lysosomal function 
negatively impacts mitochondria15. Supporting this, autophagy-enhancing drugs such as rapamycin have neuro-
protective effects against the mitochondrial complex I inhibitor rotenone in cellular models of PD21. Interestingly, 
mitochondrial dysfunction induced by rotenone treatment alters the expression of lysosomal genes, perhaps 
because mitophagy induction regulates mitochondrial and lysosomal biogenesis through nuclear translocation 
of transcription factors22,23. Recent studies have documented mitochondria-lysosome membrane contact sites, 
which enable bidirectional regulation of mitochondrial and lysosomal dynamics, and have demonstrated how 
mitochondrial impairment supresses autophagic flux, suggesting a complex mutual relationship between these 
two cellular compartments24–28.
The exact relationship between mitochondrial and lysosomal function in PD is not well defined23,25,26, how-
ever, and its role in the pathogenic process remains uncertain. By studying the lysosomal compartment and func-
tion in the context of parkin deficiency, we sought to address whether chronic mitochondrial dysfunction causes 
lysosomal impairment, contributing to PD pathogenesis. For this purpose, we studied isogenic iPSC-derived 
neuronal cultures with and without PARK2 mutation, which as we have recently shown, leads to several mito-
chondrial defects29. Parkin deficiency resulted in a number of perturbations including altered lysosomal content, 
morphology, and function as well as autophagic changes. This indicates a link between parkin deficiency and 
lysosomal disturbances.
Results
Identical differentiation potentials of PARK2 Ko ipScs and control lines. To study the disease 
mechanism underlining PARK2-mediated PD, we analysed two isogenic iPSC lines that were created from a 
healthy control iPSC line, where KO of the PARK2 gene was created by zinc finger nuclease gene editing technol-
ogy30. Detailed cell line information is reported in our recent studies29,31.
PARK2 KO and isogenic control iPSC-derived neuronal stem cells (NSCs) were differentiated simultaneously 
to assess the efficiency of midbrain dopaminergic neuron yield (Fig. 1A). Figure 1B shows representative immu-
nofluorescence pictures of cultures differentiated for 25 days, revealing a large percentage of MAP2 + mature 
neurons with distinct cell bodies and long branched processes forming highly interconnected networks. No 
apparent difference in the percentage of mature neurons was observed (control: 69.8 ± 1.0%, PARK2: 68.4 ± 0.9%) 
(Fig. 1C). The differentiated cells were also positive for NeuN and synaptophysin markers, which confirmed their 
maturity29,31. Many of the generated neurons co-localized with the dopaminergic marker tyrosine hydroxylase 
(TH), which is the rate-limiting enzyme in the production of dopamine. No apparent difference in the amount 
of TH + dopaminergic neurons was observed between cell lines (control: 25.25 ± 1.0%, PARK2: 24.6 ± 1.1%) 
(Fig. 1D). We also found GABAergic+ neurons and a small population of GFAP + astrocytes in the cultures31. 
Western blot analysis showed similar amounts of MAP2 and TH protein expression between control and PARK2 
KO cell lines, confirming the immunofluorescence staining (Fig. 1E,F). qRT-PCR analysis detected the pres-
ence of midbrain dopaminergic specific markers (EN1, NURR1, GIRK2) in the differentiated neuronal cultures 
(Fig. 1G). Both lines showed comparable expression levels with no significant differences. These data indicate that 
PARK2 KO does not affect the neuronal differentiation potential of the iPSC-derived NSCs, as both the PARK2 
KO and isogenic control lines were equally efficient in generating midbrain dopaminergic neurons.
proteomic changes and increased lysosomal content in PARK2 Ko neurons. As earlier reported, 
we subjected PARK2 KO and isogenic control neuronal cultures to a mass spectrometry-based proteomic anal-
ysis that led to the identification and quantification of a large number of proteins (dataset accessible through the 
ProteomeXchange Consortium with the identifier PXD008894). We described dysregulation of 119 mitochon-
drial proteins in neurons with PARK2 KO. The protein changes indicated disturbances in oxidative stress defense, 
mitochondrial respiration and morphology, which were confirmed by functional assays29. Based on this recently 
published dataset29, we also detected significant changes in the levels of 22 lysosomal proteins in PARK2 KO 
neurons (Table 1). A number of these proteins were important for vesicle-mediated protein trafficking through 
the endosomal-lysosomal system and for the ALP pathway (Table 1). Lysosomal perturbations were thus present 
in the PARK2 KO neurons and led us to examine the overall lysosomal content of PARK2 KO neurons. Western 
blotting showed that levels of lysosomal-associated membrane protein 1 and 2A (LAMP1/2A), which are often 
used as general markers for lysosomes, were significantly elevated (Fig. 2A,B), pointing to an overall increased 
lysosomal content in the PARK2 KO neurons.
TEM evidence for lysosomal abnormalities in PARK2 Ko neurons. To further investigate the lyso-
somal perturbations suggested by the proteomic analysis, we applied transmission electron microscopy (TEM) 
analysis, which revealed several ultrastructural disturbances within lysosome-like structures. Lysosomes are 
small electron-dense spherical organelles that are enclosed by a single membrane and have a diameter of about 
0.5–1.0 µm32. Ultrastructural assessment of the PARK2 KO and healthy control neurons detected clear differ-
ences in lysosomal morphology between the two cell lines. Lysosomes in healthy control neurons were uni-
form and displayed a homogeneous electron-dense content, whereas lysosomes in neurons with PARK2 KO 
were more heterogeneous as a substantial proportion of them presented a less electron-dense content with large 
translucent areas (Fig. 2C). Quantitative analysis showed a significant increase in the number of lysosomes rel-
ative to the total cytoplasmic area in PARK2 KO neurons compared to healthy isogenic controls (38% increase, 
p < 0.01) (Fig. 2D). The area of the individual lysosomes was increased for PARK2 KO neurons by approximately 
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40% (p < 0.01) compared to controls (Fig. 2E), thus verifying the presence of enlarged lysosomes observed for 
PARK2 KO neurons. In addition, the mean grey value (a measure of lysosomal electron-density) was significantly 
reduced for PARK2 KO neurons (20% decrease, p < 0.05) (Fig. 2F). This led us to categorize lysosomes into two 
groups according to their TEM morphology, electron-lucent (light) and electron-dense (dark), and we found 
Figure 1. General characterization of neurons derived from PARK2 KO and healthy isogenic induced 
pluripotent stem cells (iPSCs). (A) Graphical overview of the differentiation of iPSCs to neural stem cells 
(NSCs) and fully committed dopaminergic neurons. (B) Immunofluorescence analysis of MAP2 (mature 
neurons, red) and TH (dopaminergic neurons, green) expression in PARK2 KO iPSC and control iPSC lines 
at day 25 of differentiation. Cell nuclei are visualized using DAPI (blue). Representative pictures are shown. 
Scale bar: 50 µm. (C,D) Quantitative assessment of (C) MAP2 + mature neurons and (D) TH + dopaminergic 
neurons in PARK2 KO and control iPSC lines. Data are presented as mean ± SEM, n = 15, 5 independent 
differentiations. (E,F) Western blotting and densitometry analysis of (E) MAP2 and (F) TH protein expression 
levels in PARK2 KO and control iPSC lines. Protein expression levels were normalized to α-actin. Full-length 
blots are presented in Supplementary Fig. S1. Data are presented as mean ± SEM, n = 3, 3 independent 
experiments. (G) qRT-PCR analysis for midbrain/dopaminergic markers (EN1, NURR1, and GIRK2). GAPDH, 
18S, HPRT were used as endogenous references. Data were normalized to control levels and presented as mean 
± SEM, n = 4, 2 independent experiments.
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significantly more electron-lucent lysosomes in the PARK2 KO neurons compared to controls (37.5% vs. 24.8%, 
respectively, p < 0.01) (Fig. 2G). Overall, TEM analysis revealed significant morphological changes in lysosomes 
between PARK2 KO neurons and isogenic control neurons. Lysosomes appeared to be more abundant, larger, and 
more electron-lucent (lighter) in PARK2 KO neurons than in controls.
Altered lysosomal abundance in mature PARK2 Ko neurons. To investigate the time course of the 
lysosomal accumulation during the differentiation of PARK2 KO neurons, we examined the abundance of lyso-
somes at different time points using immunofluorescence staining with the lysosomal marker LAMP1 (Fig. 3A–
E). We observed no significant differences in the pattern of LAMP1 staining between PARK2 KO and isogenic 
control neurons in the early stages of differentiation at day 0 (neural stem cell stage) and 10 (progenitor cell stage) 
(Fig. 3A,B,F). After 25 days of differentiation, when approximately 70% of the neurons were mature (Fig. 1C), 
PARK2 KO neurons had a significantly increased area of lysosomes per cell, consistent with the obtained TEM 
data. Thus the area of LAMP1 + staining per DAPI + nuclei in PARK2 KO neurons was approximately 25% larger 
than that in control neurons (Fig. 3C,F). The lysosomal area increased in both cell lines proportional to the time 
of differentiation, through with greater lysosomal accumulation in PARK2 KO neurons (Fig. 3A–F). Moreover, at 
the later stages of differentiation, lysosomes were well resolved as puncta in healthy control neurons (Fig. 3C–E, 
upper panel, white arrows). In contrast, lysosomes appeared enlarged and clustered in PARK2 KO cells (Fig. 3C–E, 
lower panel, red arrows). Altogether, these findings demonstrate that parkin dysfunction causes lysosomal accu-
mulation and altered subcellular distribution in mature human PARK2 KO neurons in a time-dependent manner.
Mitochondrial uncoupling leads to lysosomal accumulation. The mitochondrial alterations in 
PARK2 KO neurons, indicated by our proteomics study29, were confirmed by qualitative analysis of TEM pic-
tures. Ultrastructural assessment of TEM micrographs revealed that mitochondria in PARK2 KO neurons were 
often accumulated in the perinuclear region and they appeared swollen with a decreased matrix density and 
irregular cristae. In contrast, mitochondria in healthy, isogenic control neurons had a typical oval appearance 
with well-organized cristae and were distributed more homogeneously throughout the cell cytoplasm (Fig. 4A). 
In addition, a similar observation of increased mitochondrial content, especially visible in the perinuclear area 
of the mutated cells, was confirmed by immunofluorescence staining for the mitochondrial outer membrane 
protein TOM20 (Fig. 4B) as earlier reported29. Moreover, a significantly enhanced ROS production was detected 
in PARK2 KO neurons (Fig. 4C).
To investigate whether the accumulation of lysosomes observed in PARK2 KO neurons at day 25 was a direct 
consequence of mitochondrial impairment, we studied the lysosomal response to mitochondrial stress caused 
Accession Gene name Description
PARK2 KO/
Control q-value
Unique 
Peptides
P27449 ATP6V0C V-type proton ATPase 16 kDa proteolipid subunit 1.56 0.005 4
Q6IQ22 RAB12 Ras-related protein Rab-12 1.31 0.014 9
Q9Y5W7 SNX14 Sorting nexin-14 1.30 0.018 2
Q8IY95 TMEM192 Transmembrane protein 192 1.25 0.025 2
O15400 STX7 Syntaxin-7 1.23 0.036 13
Q96GC9 VMP1 Vacuole membrane protein 1 1.21 0.035 3
Q9H267 VPS33B Vacuolar protein sorting-associated protein 33B 0.87 0.039 7
P78537 BLOC1S1 Biogenesis of lysosome-related organelles complex 1 subunit 1 0.85 0.042 3
Q969J3 BORCS5 BLOC-1 related complex subunit 5 0.85 0.037 2
Q9H305 CDIP1 Cell death-inducing p53-target protein 1 0.84 0.028 2
P07858 CTSB Cathepsin B 0.84 0.047 2
Q9UN37 VPS4A Vacuolar protein sorting-associated protein 4A 0.83 0.036 8
P86790 CCZ1B Vacuolar fusion protein CCZ1 homolog B 0.82 0.020 3
Q8TAF3 WDR48 WD repeat-containing protein 48 0.81 0.042 8
O14964 HGS Hepatocyte growth factor-regulated tyrosine kinase substrate 0.79 0.015 5
P61073 CXCR4 C-X-C chemokine receptor type 4 0.79 0.016 3
O43237 DYNC1LI2 Cytoplasmic dynein 1 light intermediate chain 2 0.74 0.017 19
Q01484 ANK2 Ankyrin-2 0.72 0.009 167
P61916 NPC2 NPC intracellular cholesterol transporter 2 0.69 0.020 3
P60520 GABARAPL2 Gamma-aminobutyric acid receptor-associated protein-like 2 0.67 0.004 6
P98164 LRP2 Low-density lipoprotein receptor-related protein 2 0.63 0.003 16
Q9H492 MAP1LC3A Microtubule-associated proteins 1 A/1B light chain 3 A 0.57 0.003 2
Table 1. Changes in lysosomal proteins identified by proteomic analysis. Ratio of lysosomal protein levels 
in PARK2 KO neurons compared to that of controls; q-value (FDR-adjusted p-value) and number of unique 
peptides, n = 3, data based on three independent experiments.
5Scientific RepoRtS |        (2020) 10:10278  | https://doi.org/10.1038/s41598-020-67091-6
www.nature.com/scientificreportswww.nature.com/scientificreports/
by carbonyl cyanide m-chlorophenyl hydrazine (CCCP), a proton ionophore that collapses the proton electro-
chemical gradient across membranes and is thus a potent uncoupler of respiratory chain function and oxidative 
phosphorylation33. To determine the optimal exposure time, the neurons were treated with 10 µM CCCP for 24, 
48, 72 and 96 hrs, respectively. The number of cells did not change significantly over time upon CCCP treatment, 
however, there was a clear trend towards a decreased number of cells after 72 and 96 hrs of exposure (Supp. 
Fig. S5). Based on these results, we chose 48 h of exposure for the following experiments. This lead to an increase 
of the lysosomal area in control cells to a level similar to that of untreated PARK2 KO neurons (41.8 vs. 40.15 arbi-
trary units, respectively, p = 0.98), strongly indicating that mitochondrial function impairment leads to lysoso-
mal accumulation. CCCP treatment of PARK2 KO neurons resulted in further enhancement of LAMP1 staining 
(Fig. 4D,E), consistent with the hypothesized mitochondrial dysfunction present in these cells and indicating 
that this is a general consequence of mitochondrial dysfunction. Taken together, these data show that exposure 
to mitochondrial stressors, like CCCP, results in elevated lysosomal area in both PARK2 KO and healthy neurons. 
This provides further evidence of a causative link between mitochondrial dysfunction and lysosomal alterations.
perturbed lysosomal function and autophagic changes in PARK2 Ko neurons. To determine 
whether the alterations in lysosome protein levels and overall organelle structure may impact lysosomal func-
tion, we performed several functional assays. We first assessed lysosomal intracellular activity (general enzyme 
activity) and found a significant >30% reduction (p < 0.05) in overall functional activity of lysosomes in PARK2 
KO neurons compared to controls (Fig. 5A,B). To further investigate the impairment of lysosomal function, we 
additionally monitored the activity of two essential lysosomal enzymes, β-galactosidase (β-Gal, Fig. 5C,D) and 
β-glucocerebrosidase (GCase, Fig. 5E–I). β-Gal activity was linear over the assay time, and a clear reduction 
was observed for the PARK2 KO neurons compared to controls, whose pattern was more similar to the positive 
Figure 2. PARK2 KO neurons exhibit aberrant lysosomes. (A,B) Western blotting analysis of the abundance 
of lysosomal markers, (A) LAMP1 and (B) LAMP2A. Expression levels were normalized to β-actin and are 
shown relative to control neurons. Full-length blots are presented in Supplementary Fig. S2. Data are presented 
as mean ± SEM of 3 independent differentiations (n = 3). Student’s t-test, *p < 0.05, and **p < 0.01. (C) 
Representative TEM micrographs showing the ultrastructure of lysosomes in healthy control (upper images) 
and PARK2 KO (bottom images) neurons. Scale bars: 1 µm, 100 nm. (D) Quantification of the lysosomal 
abundance relative to cytoplasm showing lysosomal accumulation in PARK2 KO neurons. (E) Lysosomal size, 
as a measurement of average area of the individual lysosomes, was increased in PARK2 KO neurons. (F) Mean 
Grey Value of individual lysosomes was reduced in PARK2 KO neurons. (G) Percentage of electron-lucent 
lysosomes among all lysosomes in a given neuronal population. Data are presented as mean ± SEM, n = 5–6 
TEM grids, 3 independent differentiations (in total 45 TEM micrographs per cell line were analysed). Student’s 
t-test, *p < 0.05, and **p < 0.01.
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control included in the assay (Fig. 5C). Calculation of the specific β-Gal activity confirmed a reduced activ-
ity in the PARK2 KO neurons compared to healthy isogenic controls (approximately 20% decrease, p < 0.01) 
(Fig. 5D). Contrarily, the activity of the lysosomal enzyme GCase, encoded by the PD-related GBA gene, was 
significantly increased in the PARK2 KO neurons (approximately 42% increase in total cell homogenate, p < 0.001 
and 21% increase in lysosomal fraction, p < 0.05) (Fig. 5E,F). As the protein levels of GCase were not significantly 
increased (Fig. 5G,H), the enhanced GCase activity was not simply an effect of increased lysosomal numbers or 
enlargement, but may reflect a compensatory functional activation (Fig. 5E–I).
In order to establish if the alterations detected in the lysosomal function also affected the autophagic pro-
cess, as alluded to by the proteomic analysis (Table 1), we used Western blotting to analyse the expression of 
microtubule-associated proteins 1A/1B light chain 3A (LC3A, gene MAP1LC3A in Table 1), LC3B and p62 since 
these proteins are commonly used for the detection of autophagic activity34–36. The total amount of LC3A and 
LC3B proteins was significantly decreased in PARK2 KO neurons at baseline, confirming the results of the pro-
teomic analysis (Table 1, Fig. 6A–C). LC3-II (LC3A-II and LC3B-II) and p62 protein turnover was measured in 
the presence and absence of bafilomycin A1, which inhibits lysosomal acidification and fusion of autophagosomes 
with the lysosome. The levels of LC3A-II and LC3B-II were not significantly changed at baseline in PARK2 KO 
neurons compared to controls. For both cell lines bafilomycin A1 treatment did not affect LC3A-II levels, while 
a trend towards increasing LC3B-II levels after treatment was observed, though this did not reach statistical 
significance (p = 0.061 for untreated vs. treated control neurons; p = 0.057 for untreated vs. treated PARK2 KO 
neurons) (Fig. 6A,D,E). No significant change was detected between untreated control and PARK2 KO neurons 
when analysing p62 expression. Control neurons showed a significant increase in the p62 level after bafilomycin 
A1 treatment, whereas this was not seen for PARK2 KO neurons, where the protein level was unaltered after the 
treatment (Fig. 6A,F). Overall, the PARK2 KO neurons showed unaffected total LC3-II flux and decreased p62 
flux compared to healthy control neurons (Fig. 6G,H). Taken together, our data provide evidence of impaired 
lysosomal activity and autophagic disturbances in PARK2 KO neurons.
Figure 3. Increased lysosomal area in mature PARK2 KO neurons. (A–E) Temporal changes in LAMP1 
(green) immunoreactivity in iPSC-derived neurons from a healthy control and PARK2 KO cells. Cell nuclei 
were visualized using DAPI (blue). Scale bar: 20 µm. (F) Quantification of the area of LAMP1 + lysosomes 
normalized to the number of DAPI + nuclei showing no difference between PARK2 KO and control cells at 
days 0 and 10, and a significant increase at day 25 and later time points. Data are presented as mean ± SEM of 3 
independent differentiations (n = 9). Student’s t-test, **p < 0.01, ***p < 0.001, ns: not significant.
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Antioxidant treatment ameliorates lysosomal accumulation in PARK2 Ko neurons. To further 
investigate the connection between mitochondrial dysfunction and lysosomal disturbances, we tested whether 
antioxidant treatment in the form of N-Acetyl-L-Cysteine (NAC) by inhibiting ROS production could affect the 
lysosomal accumulation. Treatment duration time and applied doses were chosen based on the current liter-
ature37: neurons were treated with NAC (0.1 mM, 0.5 mM, 1 mM) for 48 h and subsequently ROS levels were 
determined. Surprisingly, we observed only a non-significant increase in ROS levels in PARK2 KO neurons with 
this particular batch of cells. However, a significant reduction occurred after treatment with 1 mM NAC (Fig. 7A), 
suggesting an ability of this compound to mitigate oxidative stress. Next, we aimed to investigate whether the 
applied antioxidant treatment could restore mitochondrial and lysosomal levels in parkin-deficient cells. For this 
purpose, antioxidant-treated neurons were evaluated by double immunofluorescence staining for TOM20 and 
LAMP1. Full dose-response curves are included in the Supplementary Information (Supp. Fig. S6). We were able 
Figure 4. Mitochondrial and lysosomal alterations in PARK2 KO neurons. (A) Longitudinally cut axon and 
mitochondria of control and PARK2 KO neurons at day 25 of differentiation. Lower panels show enlarged 
pictures of the areas marked by red boxes in the upper panels. Scale bar: 1 µm. (B) TOM20 (red) and DAPI 
(blue) immunofluorescence staining confirming an increase in mitochondrial abundance, especially visible in 
the perinuclear area of PARK2 KO neurons (marked with white arrows). Scale bar: 20 µm. (C) ROS production 
in control and PARK2 KO neurons. Data presented as ± SEM, n = 12, 3 independent differentiations. Student’s 
t-test, *p < 0.05 (D) LAMP1 (green) and DAPI (blue) immunofluorescence staining of PARK2 KO neurons and 
isogenic controls at day 25 after CCCP treatment (10 µM, 48 h). Scale bar: 20 µm. (E) Significant increase of the 
lysosomal area in both control and the PARK2 KO neurons after CCCP exposure. Data presented as mean ± 
SEM, n = 9, 3 independent differentiations. Two-way ANOVA, *p < 0.05, **p < 0.01, ns: not significant.
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to confirm our earlier findings of increased levels of TOM20+ and LAMP1+ staining area in PARK2 KO neurons 
when compared to controls (Fig. 7B–D). Interestingly, in PARK2 KO neurons a significant decrease in mito-
chondrial and lysosomal areas was observed after exposure to 1 mM NAC when compared to untreated neurons 
(Fig. 7B,E,F). These data provide initial evidence of the possible beneficial effects of antioxidant treatment on both 
mitochondria and lysosomes, however, further research is required for accurate understanding.
Discussion
The importance of parkin dysfunction in familial and sporadic PD is well established, but the exact mechanism 
and pathways are not well understood6,38. Parkin was first associated with mitochondrial function through stud-
ies in Drosophila M.39, but today we know that the parkin protein has multiple roles and that is crucial for the 
proper function of not only mitochondria but also lysosomes23,39. Both mitochondrial defects and lysosomal 
Figure 5. Perturbed lysosomal function in PARK2 KO neurons. (A) General intracellular lysosomal enzyme 
activity manifested by generation of the fluorescence signal in PARK2 KO and control neurons. Scale bar: 
50 µm. (B) Quantification of the signal intensity showed a significant decrease in overall functional activity 
of lysosomal enzymes in PARK2 KO neurons compared to controls. (C) Kinetics of enzymatic activity of 
β-galactosidase (β-Gal) based on relative fluorescence intensity versus time. Graph represents changes in the 
PARK2 KO neurons (blue dashed line) and control neurons (grey solid line), positive control (red dashed 
line), and blank (green dot-dash line). (D) The specific β-Gal activity was significantly reduced for the PARK2 
KO neurons. Data presented as ± SEM, n = 6, 2 independent differentiations. Student’s t-test, *p < 0.05, 
**p < 0.01. (E,F) Glucocerebrosidase (GCase) enzyme activity was significantly increased for PARK2 KO 
neurons compared to controls in both (E) total cell homogenate and (F) lysosomal fraction. (G,H) Western 
blotting showed no changes in GBA levels. Expression levels were normalized to β-actin and are shown relative 
to control neurons. Full-length blots are presented in Supplementary Fig. S3. (I) GCase enzyme activity 
normalized to GBA levels was significantly increased in PARK2 KO neurons. Data presented as ± SEM, n = 4–6, 
2–3 independent differentiations. Student’s t-test, *p < 0.05, **p < 0.01, ***p < 0.001, ns: not significant.
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function impairment can lead to neurological pathologies, suggesting functional connections between these two 
organelles40,41.
We recently demonstrated prominent mitochondrial-related defects and mitochondrial proteome perturba-
tions in response to parkin deficiency29. These include disturbances in oxidative stress defense, mitochondrial 
respiration and morphology. Moreover, structural and functional analyses revealed an increase in mitochondrial 
area and dysregulation of fission-fusion dynamics29. In the present study, therefore, we explored the reciprocal 
relationship between mitochondrial and lysosomal pathways in PD by investigating the impact of parkin dysfunc-
tion on lysosome structure and function using human iPSC-derived neurons with PARK2 mutations and isogenic 
healthy controls. We found striking differences in lysosomal abundance, morphology, content, and activity in the 
PARK2 KO neurons. Although endo-lysosomal alterations have been documented in other parkin dysfunction 
models42,43, we believe this to be the first experimental evidence obtained from human PARK2 KO iPSC-derived 
neurons.
One of the consequences of mitochondrial deficits caused by parkin dysfunction in this cellular model of PD 
was increased lysosomal abundance and size. This altered phenotype appeared at differentiation day 25, when 
the cells also exhibited aberrant mitochondria, indicating increased vulnerability of mature neurons29. Similar 
lysosomal and mitochondrial alterations to those observed in our study were detected in mitochondrial mutants 
exhibiting disrupted mitochondrial fission-fusion processes and cristae structure and mitochondrial impair-
ment25,44–46. A recent study in mice and cellular models of mitochondrial dysfunction reported a ROS-dependent 
increase in numbers of lysosomes, suggesting a possible mechanism44. Mitochondrial activity is required to main-
tain proper lysosomal structure and function, as demonstrated by studies applying chemical inhibition of the 
Figure 6. Autophagic changes in PARK2 KO neurons. (A–H) Investigation of autophagy-related protein 
expression in PARK2 KO neurons. (A) Differentiated cells were incubated with 10 nM bafilomycin A1 (BAF) 
for 6 h or with equivalent amount of DMSO as vehicle (UNTR), and Western blotting was performed for LC3A, 
LC3B and p62. Total (B) LC3A (LC3A-I + LC3A-II) and (C) LC3B (LC3B-I + LC3B-II) levels were normalized 
to actin. (D) LC3A-II, (E) LC3B-II and (F) p62 levels for each group were calculated by densitometric analysis 
and normalized to actin. Full-length blots are presented in Supplementary Fig. S4. (G) Total LC3-II flux and (H) 
p62 flux calculated as the ratios LC3-II (BAF)/LC3-II (UNTR) and p62 (BAF)/p62 (UNTR), respectively. Data 
are presented as mean ± SEM, n = 3–4, two independent differentiations. Student’s t-test (B,C,G,H) or one-way 
ANOVA (D-F), **p < 0.01, ***<0.001, ns: not significant.
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electron transport chain and by in in vitro and in vivo genetic models of mitochondrial dysfunction. Specifically, 
disruption of mitochondrial function results in the accumulation of enlarged endo-lysosomal structures25,44,47,48.
Our study supports these observations as lysosomal area increased after uncoupling of mitochondrial function 
by CCCP treatment in both neuronal populations. CCCP-treated control neurons contained almost equal area of 
lysosomes per cell as PARK2 KO untreated neurons, pointing to an association between lysosomal accumulation 
and mitochondrial membrane depolarization caused by CCCP. In line with this, an increase in the lysosomal 
level was found in HeLa cells treated with the electrogenic ionophore agents CCCP and ionomycin49. However, 
it cannot be excluded that CCCP interferes with lysosomes independently of mitochondria by impairing the 
vacuolar-type H+ -ATPase, as previously suggested, and therefore this should be further investigated22,50. Acute 
CCCP treatment was recently found to promote lysosomal biogenesis through activation of transcription factor 
EB (TFEB)23,51. TFEB regulates both mitochondrial and lysosomal biogenesis and is translocated to the nucleus 
upon starvation, mitophagy induction, and lysosomal functional impairment52–54. Whether TFEB translocation/
activation is responsible for the increased lysosomal content in PARK2 KO neurons remains to be examined.
Another contributing factor to the increased lysosomal content in PARK2 KO neurons could be an impaired 
lysosomal degradation capacity and the build-up of undegraded cargo, as reported in iPSC-derived dopamin-
ergic neurons from GBA patients55,56. Applying TEM we detected an increased number of large electron-lucent 
lysosomes in PARK2 KO neurons. The normally dark lumen is characteristic for primary lysosomes32 and 
the observed accumulation of less electron-dense lysosomes in PARK2 KO neurons might represent secondary 
lysosomes in which digestion of the contents is perturbed. Similar observations of enlarged and electron-lucent 
lysosomes are described in lysosomal storage disorders57–59. Supporting this notion, the overall lysosomal enzyme 
activity was significantly decreased in the PARK2 KO neurons.
The impaired lysosomal enzyme activity we observed in PARK2 KO neurons could be associated with auto-
phagic disturbances as reduced autophagic flux was documented in a recent study performed on PARK2-PD 
fibroblasts and in iPSC-derived neurons from patients with GBA mutation and sporadic PD53,60,61. Indeed, our 
Figure 7. Effect of antioxidant treatment on PARK2 KO neurons. (A) ROS production in PARK2 KO neurons 
at day 26 after NAC treatment (0.1 mM, 0.5 mM and 1 mM) for 48 h. Data presented as ± SEM, n = 8, two 
independent differentiations. One-way ANOVA, **p < 0.01, ns: not significant. UNTR: untreated, NAC: 
N-Acetyl-L-Cysteine. (B) Representative immunofluorescence images of TOM20 (mitochondria, red) and 
LAMP1 (lysosomes, green) in untreated PARK2 KO neurons and after NAC exposure for 48 h, compared 
to untreated healthy control cells. Cell nuclei are visualized using DAPI (blue). Scale bar: 50 µm. (C,D) 
Quantification of the area of (C) TOM20 + mitochondria and (D) LAMP1 + lysosomes normalized to the 
number of DAPI + nuclei in untreated PARK2 KO neurons compared to healthy controls at day 26. (E,F) 
Quantitative assessment of (E) TOM20 + mitochondrial area and (F) LAMP1 + lysosomal area in PARK2 KO 
cells after NAC (1 mM) treatment compared to untreated PARK2 KO. Data are presented as mean ± SEM, n = 6, 
two independent differentiations. Student’s t-test, *p < 0.05, **p < 0.01 ns: not significant. UNTR: untreated, 
NAC: N-Acetyl-L-Cysteine.
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data showed perturbations in the total levels of LC3A and LC3B, key proteins in the autophagic process, which 
were significantly decreased in PARK2 KO neurons. However, autophagic activity, as indicated by the levels of 
LC3A-II and LC3B-II with and without inhibition of autophagosome-lysosome fusion, was not significantly 
affected. For both control and PARK2 KO neurons we found a strong tendency towards increased LC3B-II levels 
following bafilomycin A1 treatment, though this did not reach statistical significance. Contrarily, when analysing 
p62 levels under the same conditions, a significant increase was seen for control neurons with bafilomycin A1 
treatment, which was not present for the PARK2 KO neurons, pointing towards impaired autophagic degradation 
in the latter. Overall, this indicates that autophagic changes are present in PARK2 KO neurons, although our 
results are not sufficient to determine whether autophagic flux is affected.
Lysosomal accumulation in PARK2 KO neurons, assessed by LAMP1 staining, was increasing progressively 
with time. Therefore, it would be highly interesting to investigate if a similar finding is to be detected with respect 
to the loss of lysosomal activity and whether the autophagic perturbations are more pronounced and unambig-
uous at later stages.
GCase activity was significantly increased in the PARK2 KO neurons, whereas both β-Gal activity and overall 
lysosomal enzymatic activity were reduced. This points to the activation of compensatory mechanisms to increase 
GCase activity, as the total protein level of GCase was unchanged. A direct interaction between parkin and GCase 
could explain such a link, as parkin can directly interact with and mediate degradation of mutant GCase62. This 
was not the case for wild type GCase, however, and further studies are needed to address the interplay between 
GCase activity and parkin dysfunction.
A recent study on cellular models of mitochondrial dysfunction induced by chemical stressors or deletion of 
mitochondrial proteins including PINK1 also documented impaired lysosomal enzyme activity. These changes 
were dependent on ROS levels, as antioxidant treatment could revert the observed phenotypes25. Given that the 
PARK2 KO neurons have decreased levels of antioxidant defence enzymes29, a similar mechanism could be rel-
evant in the present study. We observed significantly elevated ROS levels in our PARK2 KO cells based on three 
independent differentiations, indicating that increased ROS could be a key factor here as well. However, it should 
be noted that when performing the NAC treatment experiment, we did not observe the baseline increase in 
PARK2 KO ROS levels. We hypothesize that this discrepancy could relate to variation between batches of NSCs, 
causing the ROS phenotype to only be detectable at a later time point during differentiation. This is based on 
observations of slight variation between batches of NSCs in when certain phenotypes appear (data not shown). 
Despite the lacking baseline difference in ROS production in these experiments, antioxidant treatment (1 mM 
NAC) caused a significant reduction of ROS levels and had a beneficial effect on the mitochondrial and lysoso-
mal area in PARK2 KO neurons. These results support a role for enhanced ROS production as a mediator of the 
observed lysosomal disturbances and may potentially hint to protective properties of NAC in PD. Several studies 
have suggested that NAC might have a beneficial effect in neurodegenerative diseases, such as PD, through pre-
vention of cell death caused by oxidative damage63 and facilitation of mitophagy64. However, as our observations 
of significantly increased ROS levels were not consistent, it cannot be excluded that the detected mitochondrial 
and lysosomal defects were not a direct result of ROS activity but rather a more complex mechanism of action.
conclusion
Our results indicate that the loss of parkin causes several lysosomal perturbations affecting their abundance, 
morphology, content, and activity. Taken together with our previous data, these findings indicate a causal link 
between two major pathological features of PD, namely mitochondrial defects and lysosomal dysregulation, sup-
porting the idea of a direct pathogenic feedback between the two organelles. Future efforts should focus on the 
identifying the molecular mechanistic pathways that connect mitochondrial and lysosomal perturbations with 
the aim of developing therapeutic approaches for PD.
Methods
ethics statement. The Research Ethics Committee of the Region of Southern Denmark approved the study 
prior to initiation (S-20130101). All use of human stem cells was performed in accordance with the Danish 
national regulations, the ethical guidelines issued by the Network of European CNS Transplantation and 
Restoration (NECTAR) and the International Society for Stem Cell Research (ISSCR).
cccp (cyanide m-chlorophenyl hydrazine) and NAC (N-Acetyl-L-Cysteine) treatments. CCCP 
and NAC solutions were prepared by dissolving in DMSO (all Sigma). At day 24 of differentiation cells were 
treated for 48 h with CCCP (10 µM), NAC (0.1 mM, 0.5 mM, 1 mM) or with equivalent dose of vehicle (DMSO).
In vitro propagation and differentiation of neural stem cells (nScs). PARK2 KO and healthy 
isogenic control NSC cell lines were provided by XCell Science Inc. (Novato, CA, USA)30. NSC lines were 
propagated according to well-established, standard protocols, using Geltrex-(Thermo Fisher) coated plates in 
Neurobasal Medium (Thermo Fisher) supplemented with NEAA, GlutaMax-I, B27, supplement (Thermo Fisher), 
penicilin-streptomycin, and bFGF. Cells were enzymatically passaged with Accutase (Thermo Fisher) when 
80–90% confluent. NSCs were differentiated according to a commercially available dopaminergic differentiation 
kit (XCell Science Inc., Novato, CA, USA) for at least 25 days. Differentiation was divided into two parts: an 
induction phase, where NSCs were differentiated into dopaminergic precursors, and a maturation phase, where 
the dopaminergic precursor cells were differentiated into mature dopaminergic neurons. The differentiations 
were carried out at 37 °C in a low O2 environment (5% CO2, 92% N2, and 3% O2). The cells were seeded onto wells 
coated with Poly-L-Ornithine (Sigma) and Laminin (Thermo Fisher) at a density of 50,000 cells/cm2. Complete 
DOPA Induction Medium (XCell Science) supplemented with 200 ng/ml human recombinant Sonic Hedgehog 
(Peprotech) was changed every second day for the first nine days of differentiation. The cells were passaged at day 
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5 and 10 and seeded at a desired cell density. The medium was switched to Complete DOPA Maturation Medium 
A and B (XCell Science) at day 10 and 16, respectively.
Quantitative real time polymerase chain reaction (qRT-PCR). Cells were harvested using cold 
Trizol reagent according to the manufacturer’s instructions (Life Technologies). RNA purification was performed 
through columns (RNeasy Mini Kit, Qiagen) and treated with DNazeI Kit according to the manufacturer’s 
instructions. cDNA was synthesized using the High Capacity cDNA Archive Kit (Applied Biosystems, Thermo 
Fisher) according to the manufacturer’s introductions. cDNA was processed by qRT-PCR analysis using a pro-
tocol customized according to the instructions of the AB Fast-7900HT System (Applied Biosystems, Thermo 
Fisher). The expression level of the dopaminergic markers was analysed using the comparative method (2-ddCt) 
and quantified relative to the expression of the three housekeeping genes GAPDH, 18 S, HPRT. Relative gene 
expression was assessed using the following TagMan assays: GAPDH, Hs02758991_g1; 18 S, Hs03003631_g1; 
HPRT, Hs02800695_m1; EN1, Hs00154977_m1; NURR1, Hs00428691_m1; GIRK2, Hs00158423_m1.
Mass spectrometry (MS)-based proteomics. Sample preparation, labelling and enrichment of phos-
phorylated peptides. PARK2 KO and control neuronal cultures were collected on ice in phosphate-buffered 
saline (PBS, Thermo Fisher) with protease (Complete Tablets, Roche) and phosphatase (PhosSTOP Tablets, 
Roche) inhibitors. The QProteome Mitochondria Isolation Kit (Qiagen) was used according to the manufac-
turer’s instructions and samples were denatured, reduced and enzymatically digested as previously described29. 
Peptides were desalted as previously described29 and labelled with Tandem Mass Tag (TMT) Sixplex Isobaric label 
Reagents (Thermo Fisher) according to the manufacturer’s instructions. Phospho-peptide enrichment was essen-
tially performed as earlier described29,65. Mono-phosphorylated and non-modified peptides were fractionated by 
hydrophilic interaction liquid chromatography (HILIC) as well as high pH fractioning to increase coverage prior 
to liquid chromatography tandem mass spectrometry (LC–MS/MS) as described previously29,65.
LC-MS/MS. The samples were analysed by a nano-Easy LC system (Thermo Fisher Scientific) connected online 
to a QExactive Mass Spectrometer (Thermo Fisher Scientific). All peptide fractions were resuspended in 0.1% for-
mic acid (FA) and loaded onto a 3 cm 100 µm inner diameter pre-column using the nano-Easy LC. The peptides 
were eluted directly onto the analytical column using different gradients. Depending on the samples based on the 
HILIC, the gradient was from 1–30% solvent B ((95% acetonitrile (ACN), 0.1% FA) for 60 or 90 min, 30–50% sol-
vent B for 10 min, 50–100% solvent B for 5 min, 100% solvent B for 8 min. All LC–MS/MS runs were performed 
using an analytical column of 17 cm × 75 µm inner diameter fused silica, packed with ReproSil–Pur C18 AQ 
reversed-phase material (Dr. Maisch, GmbH). Mass spectrometry was performed using higher energy collision 
(HCD) fragmentation on a QExactive instrument. MS settings: a full MS scan in the mass range of 400–1400 Da 
was performed in the Orbitrap with a resolution of 120,000 full width half maximum (FWHM) and a target value 
of 3 × 106 ions. For each full scan the 12 most abundant ions were selected for HCD fragmentation. The fragments 
were detected at a resolution of 60,000 FWHM for a target of 1 × 105 and a maximum injection time of 60 ms 
using an isolation window of 1.2 m/z and a dynamic exclusion. All raw data were viewed in Thermo Xcalibur v3.0.
MS data analysis. The raw data were processed using Proteome Discoverer (v2.1, Thermo Fisher) and 
searched against the Swissprot human database using an in-house Mascot server (v2.3, Matrix Science Ltd.). 
Databases were searched using the following parameters: precursor mass tolerance of 10 ppm, fragment mass 
tolerance of 0.02 Da, TMT 6-plex (Lys and N-terminal) as fixed modifications, and a maximum of two missed 
cleavages for trypsin. Variable modifications were NEM on Cys and N-terminal acetylation along with phos-
phorylation of Ser/Thr/Tyr for the phosphorylated group. Only peptides with a q-value up to 0.01 (Percolator), 
Mascot rank 1, and cut-off value of Mascot score > 15 were considered for further analysis. Only proteins with 
more than one unique peptide were considered for further analysis in the non-modified group.
Sample preparation for transmission electron microscopy (TEM). Cells seeded on 13 mm 
Thermanox plastic coverslips (Nunc) were primarily fixed in 3% glutaraldehyde (Merck) in 0.1 M sodium phos-
phate buffer with pH 7.2 at 4 °C for 1 h and stored in a 0.1 M Na-phosphate buffer at 4 °C until further analysis. 
When ready, the cells were embedded in 4% agar at 45 °C (Sigma) under the stereomicroscope and cut into 1–2 
mm3 blocks, which were then washed with 0.1 M Na-phosphate buffer followed by post-fixation in 1% osmium 
tetroxide in 0.1 M Na-phosphate buffer (pH 7.2) for 1 h at room temperature (RT). Cells were washed in MilliQ 
water, followed by stepwise dehydration in a series of ascending ethanol concentrations ranging from 50–99% 
EtOH. Propylene oxide (Merck) was then used as an intermediate to allow infiltration with Epon (812 Resin, 
TAAB). The following day, the agar blocks were placed in flat molds in pure Epon, which was cured at 60 °C for 
24 h. Approximately eight semi-thin sections (2 μm) from one block were cut on an ultramicrotome with a glass 
knife (Leica, Reichert Ultracut UTC). These were stained with 1% toluidine blue in 1% Borax and evaluated by 
light microscopy to locate areas with adequate number of cells for further processing. Ultra-thin sections (70 nm) 
were cut on the ultramicrotome with a diamond knife (Jumdi, 2 mm) and then collected onto TEM copper grids 
(Gilder) and stained with 2% uranyl acetate (Polyscience) and 1% lead citrate (Reynolds 1963). The samples were 
evaluated, and the images were collected using a Philips CM100 transmission electron microscope equipped with 
a Morada digital camera equipment and iTEM software system.
Morphometric analysis of TEM images. Six TEM grids from each cell line were used for analysis, and 
ten spots were randomly chosen at low magnification. Images of each spot were captured using high magnifica-
tion (19,000×). To estimate lysosomal number, all lysosomes were counted manually on each micrograph and 
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normalized to cytoplasm area. 45 images were used for each cell line. For further measurements of area and 
mean grey value, individual organelles were selected and processed manually in ImageJ software using a freehand 
selection tool, which allows creating irregularly shaped contour. In the total 75 organelles from each cell line were 
analysed.
Western blotting. Western blotting was performed using standard techniques. In brief, the cells were col-
lected on ice in lysis buffer (PBS containing phosphatase (PhosphoSTOP Tablet, Roche) and protease (Complete 
Mini Tablets, Roche) inhibitors supplemented with 1% Triton X-100). Afterwards, samples were incubated for 
30 min at 4 °C with shaking and centrifuged (10,000 rpm, 15 min, 4 °C), and the supernatants were collected. 
Samples were equalized according to the protein concentration, denatured for 10 min in NuPAGE loading buffer, 
separated by SDS-PAGE on NuPage 4–12% Bis-Tris or 3–8%Tris-Acetate gels (Invitrogen). The proteins sepa-
rated through electrophoresis were transferred onto polyvinylidene difluoride (PVDF) membranes (Invitrogen) 
followed by blocking the membranes for 60 min at 4 °C with 5% non fat dry milk in a mixture of 0.05 M TBS 
and 0.05% Tween-20. The membranes were incubated overnight at 4 °C in solution containing relevant primary 
antibodies: mouse anti-TH (Chemicon/Millipore #MAB5280) 1:2000, mouse anti-MAP2a + b (Sigma #M1406) 
1:500, rabbit anti-LAMP1 (Abcam #24170) 1:500, rabbit anti-LAMP2A (Abcam #18528) 1:500, rabbit anti-GBA 
(Abcam #154856) 1:1000, rabbit anti-LC3A (Cell Signaling #4599) 1:1000, rabbit anti-LC3B (Cell Signaling 
#3868) 1:1000, mouse anti-p62/SQSTM1 (Abcam #56416) 1:500, mouse anti-α-actin (Chemicon/Millipore 
#MAB1501) 1:6000, and mouse anti-β-actin (Abcam #49900) 1:50000. Subsequently, blots were incubated with 
an appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (DAKO #P0260 or #P0217) with 
dilution 1:2000 for 1 h at RT. Protein expression was detected with ECL reagents (Thermo Fisher) using the 
ChemiDoc MP imaging system (BioRad), and quantified by densitometry using Image Lab software (BioRad).
Immunofluorescence staining. Cells cultured on coverslips in 24-well plates (Costar) were fixed in 4% 
paraformaldehyde (PFA, Sigma) for 20 min at RT, washed twice in 0.15 M Sørensen’s buffer for 15 min and then 
permeabilized by washing three times in 0.1% Triton X-100 (Sigma) in 0.05 M TBS for 15 min at RT, followed by 
blocking in 5% goat serum (Millipore) in 0.05 M TBS for 30 min at RT. Afterwards, primary antibodies diluted 
in 5% goat serum were added to the cells in the following concentrations: rabbit anti-TH (Millipore #AB152) 
1:600, mouse anti-MAP2a + b (Sigma #M1406) 1:2000, rabbit anti-LAMP1 (Abcam #108597) 1:1000, rabbit 
anti-TOM20 (Santa-Cruz #SC-11415) 1:1000. The cells were washed three times in 0.1% Triton X-100 in 0.05 M 
TBS for 15 min at RT and incubated with fluorophore-conjugated secondary antibodies: Alexa Fluor 488 goat 
anti-rabbit IgG (Invitrogen #A11008), Alexa Fluor 488 goat anti-mouse IgG (Invitrogen #A11001), Alexa Fluor 
555 goat anti-rabbit IgG (Abcam #150078) or Alexa Fluor 555 goat anti-mouse IgG (Molecular probes #21422) 
1:500 diluted in 5% goat serum in 0.05 M TBS for 2 h at RT. The cells were washed twice in 0.05 M TBS for 15 min 
at RT and then counterstained with 10 µM DAPI (Sigma) for 15 min at RT to stain all nuclei. Finally, cells were 
mounted onto glass slides using ProLong® Diamond mounting medium (Molecular Probes).
fluorescent image analysis. Fluorescence images were acquired on a FluoView FV1000MPE – 
Multiphoton Laser Confocal Microscope (Olympus) 20X or 60X magnification, in a blinded manner on five 
randomly chosen confocal fields per coverslip from independent experiments. TH + dopaminergic neurons and 
MAP2 + mature neurons stainings were quantified manually in ImageJ using the Cell Counter plugin. Only cells 
displaying an extensive immunostaining with a well-preserved cellular morphology were counted. Lysosomal 
and mitochondrial areas were analysed automatically in ImageJ software by converting LAMP1/TOM20 images 
to binary format. All stainings were normalized to total cell numbers as quantified by DAPI + nuclei analysis in 
CellProfiler or ImageJ software.
RoS evaluation. ROS levels were measured using ROS-Glo™ Assay Kit (Promega) according to the manu-
facturer’s instructions. Briefly, cells were plated in a 96-well plate (5–10.000 cells/well). H2O2 Substrate was added 
to each well and incubated for 1–2 h at 37 °C. Then, ROS-Glo™ Detection Solution was added and the plate was 
incubated for additional 20 min at RT. The luminescence signal (RLU) was recorded using an Orion L Microplate 
Luminometer (Titertek Berthold). The RLU values were corrected for total cell numbers.
total lysosomal intracellular activity assay. Total lysosomal intracellular activity was measured using 
Lysosomal Intracellular Activity Assay Kit (Cell-Based) (BioVision) according to the manufacturer’s protocol. 
Briefly, cells were plated on 13 mm glass coverslips in a 24-well culture plate and incubated for 8 h in medium 
supplemented with 10% FBS at 37 °C. The media were removed and replaced with fresh aliquots supplemented 
with 0.5% FBS. Self-Quenched Substrate was added to each well, and the plate was incubated for 1 h at 37 °C. Ten 
minutes before the end of incubation, 1:1000 Hoechst solution (Sigma) was added to each well to stain nuclei. 
After incubation, the cells were analysed under fluorescence microscope with 488 nm excitation filter to visualize 
the fluorescence of released Self-Quenched Substrate, which was proportional to the total lysosomal intracellular 
activity.
Fluorescence images were acquired on a FluoView FV1000MPE – Multiphoton Laser Confocal Microscope 
(Olympus) 60X magnification. They were analysed automatically in ImageJ software by converting images to 
binary format. Total area of the staining was normalized to total cell numbers as quantified by Hoechst+ nuclei 
analysis in ImageJ software.
β-galactosidase (β-Gal) activity assay. β-Gal activity was measured using Fluorometric β-Galactosidase 
Activity Assay Kit (BioVision) according to the manufacturer’s protocol. Briefly, cells were plated in a 6-well plate 
and homogenized with ice-cold β-Gal Assay Buffer and kept on ice for 10 min. Cell lysates were transferred to 
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Eppendorf tubes and centrifuged at 10,000 g, 4 °C for 5 min, and then supernatants were collected. Diluted β-Gal 
Positive Control and supernatant were transferred in triplicates into desired wells in a 96-well black plate. The 
volume of samples and Positive Control wells was adjusted with β-Gal Assay Buffer. Required amount of Reaction 
Mix (containing β-Gal Assay Buffer and β-Gal Substrate) was prepared, and added to each well. Fluorescence 
signal (Ex/Em = 480/520 nm) was measured in kinetic mode, and the Fluorescein Standard Curve was read in 
Endpoint mode.
β-glucocerebrosidase (Gcase) activity assay. To isolate the lysosomal fraction, cell pellets, collected as 
earlier described, were resuspended in PBS with protease inhibitor (Complete Mini Tablets, Roche) and homog-
enized with a 5 ml syringe with a 21 G needle. This was followed by centrifugation (1,000 g, 10 min, 4 °C) to 
pellet nuclei and cell debris. The supernatant was collected and centrifuged (20,000 g, 30 min, 4 °C) to pellet the 
lysosomal fraction. Total cell pellets or lysosomal fraction pellets were sonicated at 10 amp for 10 sec in citrate 
phosphate buffer pH 5.4 consisting of 0.1 M citric acid (Sigma) and 0.2 M dibasic sodium phosphate (Sigma) 
with 0.25% (v/v) Triton X and 0.25% (w/v) taurocholic acid (Sigma). Samples were centrifuged at 800 g for 5 min 
at 4 °C, and the supernatant was collected. Then samples were diluted in citrate phosphate buffer in quadrupli-
cate. One replicate of each sample was treated with 1 mM conduritol B epoxide (CBE, Calbiochem) for 10 min 
before all samples were incubated for 1 h with 2.5 mM of the fluorescent GCase substrate methylumbillifery 
β-D-glucopyranoside (4MUG, Sigma) at 3 °C in the dark. The reaction was quenched with 1 M glycine buffer 
(Sigma) pH 10.8, and the fluorescent levels were analysed on the PHERAStar FSX plate reader (BMG Labtech). 
Values from CBE-treated wells were subtracted as background.
Autophagic flux. We explored whether LC3A-II, LC3B-II (markers for autophagosomal membrane) and p62 
(a cargo receptor for autophagy substrates) were degraded in a lysosomal-dependent manner by using bafilomy-
cin A1, an inhibitor of lysosomal acidification. We incubated differentiated neurons with DMSO (untreated) or 
medium containing bafilomycin A1 (10 nM for 6 h). Western blotting was performed on cell lysates using anti-
bodies against LC3A, LC3B (Cell Signaling), p62 (Abcam) and α-actin (Abcam). LC3A-II, LC3B-II and p62 band 
intensities were quantified through densitometric analysis using ImageJ software and normalized to α-actin. Total 
LC3-II autophagic flux and p62 autophagic flux were calculated as the ratios LC3-II (bafilomycin A1) /LC3-II 
(untreated) and p62 (bafilomycin A1)/p62 (untreated), respectively.
Statistical analysis. Data were analysed by GraphPad Prism 7.0 software using two-tailed unpaired 
Student’s t-test and one-way or two-way ANOVA with Tukey’s Multiple Comparison Test as appropriate. Data 
were considered statistically significant at p < 0.05 (*), p < 0.01 (**), and p < 0.001 (***). Data are presented as 
mean ± standard error of the mean (SEM).
Data availability
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 
partner repository with the dataset identifier PXD008894.
The remaining datasets used and/or analysed during the current study are available from the corresponding 
author on request.
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